Jing Yang1, Yuncheng Lv2, Yi Zhang1, Jiaoyang Li1, Yajun Chen3, Chang Liu4, Jing Zhong5, Xinhua Xiao1, Jianghua Liu1, Gebo Wen6. 1. Department of Metabolism & Endocrinology, the First Affiliated Hospital of University of South China, 69 Chuanshan Road, Hengyang, 421001, China. 2. Clinical Anatomy & Reproductive Medicine Application Institute, University of South China, 28 Changsheng West Road, Hengyang, 421001, China. 3. Department of Metabolism & Endocrinology, the Second Affiliated Hospital of University of South China, 30 Jiefang Road, Hengyang, 421001, China. 4. Department of Metabolism & Endocrinology, the Chenzhou Affiliated Hospital of University of South China, 102 Luojiajing Road, Chengzhou, 423000, China. 5. Department of Clinical Research, the First Affiliated Hospital of University of South China, 69 Chuanshan Road, Hengyang, 421001, China. 6. Department of Metabolism & Endocrinology, the First Affiliated Hospital of University of South China, 69 Chuanshan Road, Hengyang, 421001, China. geb_wen@hotmail.com.
Abstract
PURPOSE: We aimed to determine changes in miR-17-92 cluster expression in serum and granulocytes from patients with antithyroid drug (ATD)-induced agranulocytosis. METHODS: In this study, real-time polymerase chain reaction (PCR) was used to detect serum miR-17-92 expression levels in 20 ATD-induced agranulocytosis and 16 control patients. Importantly, dynamic changes in neutrophil counts from granulocytopenia to agranulocytosis were observed in 6 of the 20 patients. miR-17-92 expression levels in granulocytes of those six patients under the granulocytopenia condition were measured and compared with corresponding granulocyte samples after recovery. Additionally, the expression levels of these miRNAs in patients with type I or type II bone marrow characteristics were analyzed, and the correlation between miR-17-92 and serum free thyroxine level was analyzed. RESULTS: We found that levels of miR-17-92 expression decreased in both serum and pre-agranulocytosis granulocytes from patients with ATD-induced agranulocytosis compared with those in serum and granulocytes from both recovered patients and control patients. However, no difference among patients with either type of bone marrow characteristics was observed, and no correlation between serum miR-17-92 and free thyroxine levels was found. CONCLUSION: In ATD-induced agranulocytosis, expression of the miR-17-92 cluster is reduced in both serum and granulocytes, though this alteration does not correlate with bone marrow characteristics or thyroid function.
PURPOSE: We aimed to determine changes in miR-17-92 cluster expression in serum and granulocytes from patients with antithyroid drug (ATD)-induced agranulocytosis. METHODS: In this study, real-time polymerase chain reaction (PCR) was used to detect serum miR-17-92 expression levels in 20 ATD-induced agranulocytosis and 16 control patients. Importantly, dynamic changes in neutrophil counts from granulocytopenia to agranulocytosis were observed in 6 of the 20 patients. miR-17-92 expression levels in granulocytes of those six patients under the granulocytopenia condition were measured and compared with corresponding granulocyte samples after recovery. Additionally, the expression levels of these miRNAs in patients with type I or type II bone marrow characteristics were analyzed, and the correlation between miR-17-92 and serum free thyroxine level was analyzed. RESULTS: We found that levels of miR-17-92 expression decreased in both serum and pre-agranulocytosis granulocytes from patients with ATD-induced agranulocytosis compared with those in serum and granulocytes from both recovered patients and control patients. However, no difference among patients with either type of bone marrow characteristics was observed, and no correlation between serum miR-17-92 and free thyroxine levels was found. CONCLUSION: In ATD-induced agranulocytosis, expression of the miR-17-92 cluster is reduced in both serum and granulocytes, though this alteration does not correlate with bone marrow characteristics or thyroid function.
Authors: T S Plantinga; P Arts; G H Knarren; A H Mulder; I M Wakelkamp; A R Hermus; L A Joosten; M G Netea; P H Bisschop; W W de Herder; H J Beijers; I J de Bruin; C Gilissen; J A Veltman; A Hoischen; J W Smit; R T Netea-Maier Journal: Clin Pharmacol Ther Date: 2017-07-10 Impact factor: 6.875
Authors: Lin He; J Michael Thomson; Michael T Hemann; Eva Hernando-Monge; David Mu; Summer Goodson; Scott Powers; Carlos Cordon-Cardo; Scott W Lowe; Gregory J Hannon; Scott M Hammond Journal: Nature Date: 2005-06-09 Impact factor: 49.962
Authors: Shuangli Mi; Zejuan Li; Ping Chen; Chunjiang He; Donglin Cao; Abdel Elkahloun; Jun Lu; Luis A Pelloso; Mark Wunderlich; Hao Huang; Roger T Luo; Miao Sun; Miao He; Mary Beth Neilly; Nancy J Zeleznik-Le; Michael J Thirman; James C Mulloy; Paul P Liu; Janet D Rowley; Jianjun Chen Journal: Proc Natl Acad Sci U S A Date: 2010-02-02 Impact factor: 11.205